| Title |
Optimizing the Efficacy of First-Line Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer
|
|---|---|
| Published in |
BioDrugs, September 2012
|
| DOI | 10.2165/11584680-000000000-00000 |
| Pubmed ID | |
| Authors |
Shaotang Li, Pan Dr Chi |
| Abstract |
To assess the efficacy and safety of first-line standard chemotherapy plus bevacizumab in metastatic colorectal cancer and to explore how to optimize therapeutic efficacy. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Estonia | 1 | 3% |
| Unknown | 30 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 9 | 29% |
| Researcher | 6 | 19% |
| Other | 3 | 10% |
| Student > Master | 3 | 10% |
| Librarian | 2 | 6% |
| Other | 3 | 10% |
| Unknown | 5 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 52% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 13% |
| Agricultural and Biological Sciences | 3 | 10% |
| Arts and Humanities | 1 | 3% |
| Business, Management and Accounting | 1 | 3% |
| Other | 2 | 6% |
| Unknown | 4 | 13% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 November 2011.
All research outputs
#17,285,668
of 25,373,627 outputs
Outputs from BioDrugs
#585
of 746 outputs
Outputs of similar age
#123,770
of 187,255 outputs
Outputs of similar age from BioDrugs
#263
of 283 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 746 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.5. This one is in the 16th percentile – i.e., 16% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 187,255 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 24th percentile – i.e., 24% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 283 others from the same source and published within six weeks on either side of this one. This one is in the 5th percentile – i.e., 5% of its contemporaries scored the same or lower than it.